Abstract：
Temporal association between BNT162b2 mRNA COVID-19 vaccine and myocarditis (PCVM) has been reported. We herein present early and 6-month clinical follow-up and cardiac magnetic resonance imaging (CMR) of patients with PVCM. A retrospective collection of data from 15 patients with PCVM and abnormal CMR was performed. Clinical manifestation, laboratory data, hospitalizations, treatment protocols, and imaging studies were collected early (up to 2 months) and later. In nine patients, an additional CMR evaluation was performed 6 months after diagnosis. PCVM was diagnosed in 15 patients, mean age 17 ± 1 (median 17.2, range 14.9-19 years) years, predominantly in males. Mean time from vaccination to onset of symptoms was 4.4 ± 6.7 (median 3, range 0-28) days. All patients had CMR post diagnosis at 4 ± 3 (median 3, range 1-9) weeks, 4/5 patients had hyper enhancement on the T2 sequences representing edemaQuery, and 12 pathological Late glandolinium enhancement. A repeat scan performed after 5-6 months was positive for scar formation in 7/9 patients. PCVM is a rare complication, affecting predominantly males and appearing usually within the first week after administration of the second dose of the vaccine. It usually is a mild disease, with clinical resolution with anti-inflammatory treatment. Late CMR follow up demonstrated resolution of the edema in all patients, while some had evidence of residual myocardial scarring.
摘要：
已经报道了BNT162b2mRNACOVID-19疫苗与心肌炎（PCVM）之间的时间关联。我们在此介绍PVCM患者的早期和6个月临床随访和心脏磁共振成像（CMR）。对15例PCVM和异常CMR患者的数据进行了回顾性收集。临床表现,实验室数据,住院治疗,治疗方案,早期(长达2个月)和后期收集影像学研究.在9名患者中，诊断后6个月进行了额外的CMR评估.在15例患者中诊断出PCVM，平均年龄17±1岁（中位数17.2岁，范围14.9-19岁），主要是男性。从疫苗接种到症状发作的平均时间为4.4±6.7（中位数3，范围0-28）天。所有患者在4±3周（中位数3，范围1-9周）诊断后CMR，4/5患者在代表edemaQuery的T2序列上有超增强，和12个病理性晚期腺体增强。在7/9患者中，5-6个月后进行的重复扫描对瘢痕形成呈阳性。PCVM是一种罕见的并发症，主要影响男性，通常在第二剂疫苗给药后的第一周内出现。它通常是一种轻度疾病，具有抗炎治疗的临床分辨率。晚期CMR随访显示所有患者水肿消退，而有些人有残留心肌瘢痕的证据。
